|1.||Ding, Jian: 7 articles (12/2014 - 02/2007)|
|2.||Mizushina, Yoshiyuki: 7 articles (08/2013 - 05/2005)|
|3.||Yoshida, Hiromi: 7 articles (08/2013 - 05/2005)|
|4.||Austin, Caroline A: 7 articles (07/2011 - 05/2002)|
|5.||Schobert, Rainer: 6 articles (10/2013 - 05/2009)|
|6.||Medsger, Thomas A: 6 articles (09/2012 - 05/2003)|
|7.||Willmore, Elaine: 6 articles (02/2010 - 05/2002)|
|8.||Di Leo, Angelo: 6 articles (12/2009 - 05/2002)|
|9.||Kondapi, Anand K: 5 articles (04/2013 - 08/2004)|
|10.||Fertig, Noreen: 5 articles (09/2012 - 05/2003)|
09/01/2001 - "Topo I activity in tumor samples of responder was significantly greater than that of in nonresponders. "
11/01/2000 - "Mean topo I activity in cervical cancer (3.0 +/- 0.06 h(-1)) was significantly greater than in normal cervix tissue (0.29 +/- 0.06 h(-1)). "
10/01/1996 - "Thus, there is evidence to suggest that Topo I inhibitors may be beneficial in the treatment of CNS neoplasms on the basis of their antineoplastic activity alone, as well as their radiosensitizing effects. "
01/01/2000 - "The efficacy of topoisomerase (Topo) I-active drugs may be improved by better understanding the molecular and cellular responses of tumor compared to normal cells after genotoxic insults. "
10/01/2010 - "These results suggest that the effect of p53-dependent cell cycle arrest may be effective for topo inhibition by com-pound 5. From these findings, the action mode of alkyl p-coumarates as an anti-cancer agent is discussed."
02/01/2003 - "These studies provide biological evidence that bis(dioxopiperazine)s are capable of functional topo II poisoning in intact mammalian cells."
11/01/2000 - "In the present study we investigated whether substituents at both the 5- and 6-positions of varied terbenzimidazoles would allow for retention of topo I poisoning activity. "
11/19/2012 - "These results suggest that the anticancer activity of HQ17(3) is attributed significantly to Topo IIα poisoning. "
01/01/2006 - "Finally, drug-TFO conjugates are useful tools to investigate the mechanistic details of topo II poisoning."
08/11/2005 - "Compounds with an alpha-configuration of terminal 2,6-dideoxy sugar (compounds 1 and 3) showed higher topo II poisoning than their counterparts with the beta-configuration (compounds 2 and 4). "
03/01/2014 - "This study further supports the evidence that MLL breakpoints in therapy-related acute leukemia with MLL-AFF1 are clustered in the telomeric half of the breakpoint cluster region that contains topo II recognition sites."
03/07/1997 - "Mutagenesis and 5'-deletion studies revealed that Myb trans-activation was mediated via a Myb-binding site at positions -16 to -11 and that this region governed the bulk of basal topo IIalpha promoter activity in human leukemia cells. "
01/01/2014 - "In conclusion, the high sensitivity of leukemia cells to HQ17(3) may be associated with the reduction of topo IIα and c-Myc activities, as well as with the downregulation of the miR-17-92 cluster expression. "
11/19/2012 - "HQ17(3) irreversibly inhibits Topo IIα activity in vitro and is more cytotoxic in leukemia HL-60 cells than in Topo IIα-deficient variant HL-60/MX2 cells, which suggests that Topo IIα is a cellular target of HQ17(3). "
11/01/2001 - "We have investigated the expression of topo IIalpha in leukemic cells from 25 patients with acute leukemia by flow cytometry, separating cells of different cell cycle phases. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
04/01/2012 - "There is a lack of study concerning expression of Topoisomerase IIα (Topo IIα) and long-term results in colorectal cancer patients. "
12/24/2013 - "To explore the clinical values of detecting drug related molecules excision repair cross complementing 1 (ERCC1) and top-isomerase I (TOPO I) in individualized therapies of metastatic colorectal cancer. "
04/01/2012 - "Of 490 colorectal cancer patients accessible for Topo IIα expression, expression of Topo IIα was scored as (-) in 4 (0.8%) patients, (+) in 41 (8.4%) patients, (++) in 396 (80.8%) patients, and (+++) in 49 (10.0%) patients. "
04/01/2012 - "We aimed to investigate the relationship between expression of Topo IIα and clinicopathological parameters including overall survival in colorectal cancer. "
12/01/2007 - "Topo I expression may be part of the malignant cells' phenotype in recurrent colorectal carcinomas, suggesting a potential role for Topo I in the acquisition of a metastatic phenotype. "
|5.||Colonic Neoplasms (Colon Cancer)
03/01/1999 - "Because Topo I inhibitors have been shown to be effective in the treatment of some patients with colon cancer, we considered the possibility of using PARP cleavage as an early predictor of responsiveness to this class of agents. "
04/01/1999 - "To date, there is no correlation between the molecular characteristics of human colon cancers with response to Topo I active drugs. "
08/01/1996 - "We have used fluorescence in situ hybridisation to detect the topo I locus in a panel of breast and colon cancer cell lines. "
04/01/2000 - "The present study was undertaken to determine if (a) genistein induces topo II-mediated DNA damage in HT-29 colon cancer cells; and (b) if this damage is required to induce apoptosis. "
04/01/2000 - "Topoisomerase I (Topo I) is overexpressed in cancer colon tissues compared with normal colon tissues. "
|1.||Etoposide (VP 16)
|3.||Type II DNA Topoisomerases (Topoisomerase II)
|8.||Messenger RNA (mRNA)
|9.||Antineoplastic Agents (Antineoplastics)
|1.||Drug Therapy (Chemotherapy)